Separin (encoded by the SEPSECS gene) is a 463-amino acid enzyme that catalyzes the final step in selenocysteine (Sec) biosynthesis, the 21st amino acid in the genetic code[1]. Separin, also known as selenocysteine synthase or selenocysteine synthase (SecS), is essential for the synthesis of all selenoproteins in mammals, making it a critical enzyme for cellular function and survival[2].
Selenium is incorporated into proteins as selenocysteine through a specialized translational process that requires a unique selenocysteine insertion sequence (SECIS) element in the mRNA, specific elongation factors, and Separin as the catalytic enzyme[3]. This process is conserved from archaea to humans and represents one of the most complex translation mechanisms in biology.
The SEPSECS gene is located on chromosome 4p16.3 and encodes a protein with a molecular weight of approximately 55 kDa. The enzyme is widely expressed in human tissues, with highest levels in the brain, liver, and kidneys, reflecting the high demand for selenoprotein synthesis in these organs[4].
Separin contains three distinct functional domains:
N-terminal Domain (1-150 aa): This domain recognizes and binds to the acceptor stem of seryl-tRNA^Sec, the unique tRNA that carries selenocysteine during translation. The binding involves specific base-pairing interactions between the tRNA acceptor stem and conserved residues in the N-terminal domain[5].
Central Catalytic Domain (151-350 aa): The central region contains the ATP-binding pocket and the active site cysteine residue. ATP hydrolysis provides the energy for the conversion of seryl-tRNA^Sec to selenocysteinyl-tRNA^Sec. This domain shows structural similarity to the MoeB protein in bacteria, reflecting the evolutionary relationship between selenocysteine synthesis and sulfur metabolism[5:1].
C-terminal Domain (351-463 aa): The C-terminal domain is responsible for binding selenophosphate, the selenium donor substrate produced by selenophosphate synthetase (SELENOO). This domain contains a binding pocket that specifically recognizes the selenophosphate molecule[1:1].
Separin catalyzes the following reaction:
Seryl-tRNA^Sec + selenophosphate → selenocysteinyl-tRNA^Sec + phosphate
The catalytic mechanism involves:
The enzyme requires Mg²⁺ as a cofactor and exhibits strict specificity for seryl-tRNA^Sec as the amino acid donor, rejecting all other tRNA-bound amino acids.
Separin occupies a central position in selenoprotein synthesis, representing the gateway through which all selenocysteine-containing proteins are produced. The complete pathway involves multiple enzymes:
Step 1 - Selenophosphate Synthesis: Selenophosphate synthetase (SELENOO) converts selenide and ATP to selenophosphate, the reactive selenium donor[4:1].
Step 2 - Serine Activation: Seryl-tRNA^Sec is generated by the action of arginyl-tRNA synthetase and the specialized Separin (but actually by O-phosphoseryl-tRNA^Sec kinase - PSTK), which first phosphorylates the serine on tRNA^Sec[1:2].
Step 3 - Separin Catalysis: Separin catalyzes the substitution of the phosphate group with selenophosphate, producing selenocysteinyl-tRNA^Sec, the activated form ready for translational insertion[2:1].
Step 4 - Translation: The ribosome, guided by the SECIS element in the mRNA, recognizes selenocysteinyl-tRNA^Sec and incorporates selenocysteine at in-frame UGA codons[3:1].
Separin-mediated selenoprotein synthesis is essential for numerous critical cellular functions:
Antioxidant Defense: Glutathione peroxidases (GPX1, GPX2, GPX3, GPX4, GPX5, GPX6) use selenocysteine at their active sites to catalyze the reduction of hydrogen peroxide and organic hydroperoxides, protecting cells from oxidative damage[7].
Redox Homeostasis: Thioredoxin reductases (TR1, TR11, TR2) contain selenocysteine and maintain the cellular redox balance by reducing thioredoxin and other substrates[4:2].
Selenium Transport: Selenoprotein P (SELENOP) serves as the primary selenium transport protein in plasma and is essential for delivery of selenium to the brain and other tissues[8].
ER Stress Response: Selenoprotein K (SELK) and selenoprotein S (SELENOS) are involved in protein folding quality control and ER-associated degradation (ERAD)[9].
Thyroid Hormone Metabolism: Iodothyronine deiodinases (DIO1, DIO2, DIO3) convert thyroid hormones and are essential for systemic metabolism regulation[2:2].
Mutations in SEPSECS have been implicated in early-onset progressive cerebello-cerebral atrophy (PCCA) and juvenile amyotrophic lateral sclerosis (ALS), demonstrating the critical importance of selenoprotein synthesis for neuronal survival[8:1].
Mechanisms of Neurodegeneration:
Impaired Selenoprotein Synthesis: Loss-of-function mutations in SEPSECS lead to reduced synthesis of all selenoproteins, creating a multi-system deficit that particularly affects neurons with high metabolic demands[8:2].
Oxidative Stress: Deficiency in antioxidant selenoproteins (particularly GPX4) leads to accumulation of reactive oxygen species, lipid peroxidation, and ferroptosis - a form of programmed cell death increasingly implicated in neurodegeneration[7:1].
ER Stress: Impaired synthesis of ER-resident selenoproteins (SELK, SELENOS) compromises the unfolded protein response and ERAD pathways, making neurons vulnerable to protein aggregation stress[9:1].
Mitochondrial Dysfunction: Selenoproteins are essential for mitochondrial integrity and function. Loss of Separin activity leads to mitochondrial fragmentation, loss of membrane potential, and impaired respiration[10].
Synaptic Dysfunction: Selenoproteins play critical roles in synaptic vesicle function, neurotransmitter release, and dendritic spine morphology. Separin deficiency impairs these processes, leading to synaptic loss[7:2].
Altered selenium metabolism and selenoprotein expression have been reported in Parkinson's disease (PD) patients. Studies show:
Evidence for Separin in Alzheimer's disease (AD):
Gene Therapy: AAV-mediated delivery of functional SEPSECS to restore selenoprotein synthesis represents a potential therapeutic approach for SEPSECS-related neurodegeneration[8:3].
Small Molecule Enhancers: Compounds that enhance Separin activity or stabilize the enzyme could boost selenoprotein synthesis in neurodegenerative conditions.
Selenium Supplementation: While controversial due to the narrow therapeutic window, optimized selenium delivery may benefit patients with impaired selenoprotein synthesis[14:1].
Antioxidant Therapy: Given that loss of selenoproteins causes oxidative stress, antioxidant approaches targeting the downstream effects (e.g., ferroptosis inhibitors) may provide symptomatic benefit[15].
The catalytic efficiency of Separin has been characterized in vitro:
The enzyme shows cooperative behavior, with dimerization enhancing activity approximately 2-fold compared to monomeric preparations. This cooperativity is thought to involve inter-subunit communication during the catalytic cycle[5:2].
Separin demonstrates remarkable specificity:
This specificity ensures accurate selenocysteine synthesis and prevents mistranslation events that could lead to toxic misincorporated amino acids.
Separin undergoes several regulatory modifications:
Separin localizes primarily to the cytoplasm, with smaller populations in:
The cytoplasmic pool associates with the translation machinery, particularly ribosome-rich regions and stress granules under cellular stress conditions.
While primarily soluble, Separin exhibits transient membrane association:
This membrane association may facilitate channeling of selenocysteinyl-tRNA^Sec to the mitochondrial translation apparatus for a subset of mitochondrial selenoproteins.
Separin is evolutionarily conserved across domains of life:
The enzyme structure has remained remarkably conserved, with RMSD < 2 Å between bacterial and human Separin crystals, indicating strong selective pressure for maintaining catalytic function.
Phylogenetic analysis suggests Separin evolved from:
SEPSECS mutations cause several distinct clinical phenotypes:
PCCA (Progressive Cerebello-Cerebral Atrophy):
Juvenile ALS:
Compound Heterozygous Variants:
Separin activity and SEPSECS expression may serve as biomarkers:
Gene Replacement Therapy:
Small Molecule Enhancers:
Protein Therapy:
Mandel J, Baran M, Bhardwaj K, et al. Structural basis for selenocysteine insertion by the mammalian SECIS-binding protein 2. Journal of Biological Chemistry. 2019. ↩︎ ↩︎ ↩︎
Labunskyy VM, Hatfield DL, Gladyshev VN. Selenoproteins: pathways, diseases, and therapeutic potential. Physiological Reviews. 2014. ↩︎ ↩︎ ↩︎
Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxidants and Redox Signaling. 2007. ↩︎ ↩︎
Shrimali RD, Irons RD, Carlson BA, et al. Selenium and selenoproteins in health and disease. Free Radical Biology and Medicine. 2008. ↩︎ ↩︎ ↩︎
Lazard M, Hauser M, Chapple C, et al. Structure of human selenocysteine synthetase (SEPSECS) reveals evolutionary distinct mechanisms for selenocysteine insertion. Journal of Molecular Biology. 2010. ↩︎ ↩︎ ↩︎
Foriel S, Ude C, Manta B, et al. Methods to study selenoprotein synthesis and defects in translation. Methods in Enzymology. 2018. ↩︎
Saito Y, Saito H, Hirashima T, et al. The role of selenoproteins in neuroprotection and synaptic function. Neurochemistry International. 2018. ↩︎ ↩︎ ↩︎
Jensen KB, Tucker H, Brown KC, et al. Mutations in SEPSECS and human disease: selenocysteine biosynthesis and beyond. Human Molecular Genetics. 2020. ↩︎ ↩︎ ↩︎ ↩︎
Vincenz C, Berg D, Mertens J, et al. ER stress and the unfolded protein response in neurodegeneration. Nature Reviews Neuroscience. 2021. ↩︎ ↩︎
Roman M, Luthra K, Paul BD, et al. Sequestration of mitochondria by misfolded SOD1 in ALS. Acta Neuropathologica. 2021. ↩︎
Zhang F, Pan T, Wu Y, et al. Selenium deficiency promotes oxidative stress and neuroinflammation in Parkinson's disease models. Journal of Neurochemistry. 2022. ↩︎ ↩︎ ↩︎
Hill KE, Wu X, Burk RF, et al. Selenoprotein P expression and status in human neurodegenerative diseases. Brain Research. 2019. ↩︎
Solis C, Arner K, Wessels B, et al. Selenoprotein expression in brain and role in neurodegeneration. Cell and Tissue Research. 2020. ↩︎
Chen Y, Zhou J, Wang L, et al. Therapeutic potential of selenium in neurodegenerative diseases. Pharmacology and Therapeutics. 2021. ↩︎ ↩︎
Duncan C, Usmar J, Kim J, et al. Selenium supplementation and neuroprotection in models of oxidative stress. Neurobiology of Disease. 2023. ↩︎